The anthelmintic drugs global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Anthelmintic Drugs Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The anthelmintic drugs market size has grown strongly in recent years. It will grow from $3.00 billion in 2023 to $3.16 billion in 2024 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to the high prevalence of helminth infections, increasing public health initiatives, rise in pharmaceutical research and development, increasing awareness and education, and economic growth.
The anthelmintic drugs market size is expected to see strong growth in the next few years. It will grow to $3.90 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The growth in the forecast period can be attributed to increasing cases of parasitic infections globally, growing use of anthelmintics in livestock and pets, increasing awareness and health initiatives, and increased international travel. Major trends in the forecast period include rising demand for combination therapies, increasing focus on drug resistance management, growing adoption of personalized medicine, expansion of telemedicine in treatment monitoring, increasing research on novel drug targets, and emphasis on preventive healthcare measures.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/anthelmintic-drugs-global-market-report
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Market Drivers –
The high prevalence of parasitic infections is expected to propel the growth of the anthelmintic drugs market going forward. Parasitic infections are diseases caused by organisms that live on or inside another host, such as parasites such as protozoa, worms, or ectoparasites. Parasitic infections are fueled by poor sanitation, contaminated food or water, close contact with infected individuals or animals, inadequate hygiene, and a lack of access to clean resources. Anthelmintic drugs are used to treat infections caused by parasitic worms, effectively targeting and eliminating these parasites from the host’s body. These medications work by disrupting the parasites’ physiological functions, leading to their expulsion or death. For instance, in July 2023, according to the data published by the Centers for Disease Control and Prevention, a US-based national public health agency, the number of cyclosporiasis cases in Florida, caused by a microscopic parasite, increased twofold, rising from 254 in 2021 to 513 in 2022. Therefore, the high prevalence of parasitic infections is driving the growth of the anthelmintic drugs market.
Market Trends –
Major companies operating in the anthelmintic drugs market are focusing on developing innovative combination drugs to provide comprehensive protection against multiple parasites. Combination anthelmintic drugs are formulations that combine two or more anthelmintic agents to enhance efficacy against parasitic infections in humans and animals. They work synergistically to broaden the spectrum of activity, delay the development of drug resistance, and overcome existing resistance profiles in parasites. For instance, in January 2022, Zoetis Inc., a US-based animal health company, received approval from the U.S. Food and Drug Administration for Simparica Trio, a new label indication, allowing it to prevent infections caused by Borrelia burgdorferi, responsible for Lyme disease in dogs. Simparica Trio combines three active ingredients – sarolaner, moxidectin, and pyrantel to provide comprehensive protection against fleas, ticks, heartworms, roundworms, and hookworms.
The anthelmintic drugs market covered in this report is segmented –
1) By Drug Class: Benzimidazoles, Macrocyclic lactones, Pyrazinoisoquinolones, Tetrahydropyrimidines, Other Drug Classes
2) By Route Of Administration: Oral, Injectable
3) By Infection Type: Nematode Infections, Cestode Infections, Trematode Infections, Mixed Infections
4) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Online Pharmacies, Veterinary Clinics And Supply Stores
5) By Application: Human Anthelmintics, Veterinary Anthelmintics
Get an inside scoop of the anthelmintic drugs market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=19291&type=smp
Regional Insights –
North America was the largest region in the anthelmintic drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthelmintic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the anthelmintic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Zoetis Inc., Hetero Labs Limited, Sun Pharmaceutical Industries Ltd., Galderma S.A., Cipla Inc., Ferring Pharmaceuticals Inc., Amneal Pharmaceuticals, Inc., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Mankind Pharma Ltd., Reese Pharmaceutical Company
Table of Contents
1. Executive Summary
2. Anthelmintic Drugs Market Report Structure
3. Anthelmintic Drugs Market Trends And Strategies
4. Anthelmintic Drugs Market – Macro Economic Scenario
5. Anthelmintic Drugs Market Size And Growth
…..
27. Anthelmintic Drugs Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
